Replies to post #72951 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Thanks for that oversight of the oncology partnership space, Mav.

All the Big Pharmas have extensive research teams, who are dedicated to the task of assessing possible competing or complementary oncology therapies.
Nothing will go under their radar, least of all the DCVax platform.

And they will certainly completely disregard 'grapefruit juice' type references, that are touted by so-called investment analysts.

They know that a combo of two CI's can enhance response rates , but at the cost of increased toxicity (ipilumumab plus nivo studies) So one of their priorities is to identify synergistic therapies, that will not compound toxicity. Hence the focus on personalized vaccines.

One of our dark horse candidates is Roche.

This is an interview with Jason Coloma – VP, Global Head, Roche Partnering Oncology. I've posted it before, but for those who didn't catch it, it's very relevant to current discussions. Well worth the eight and a half minutes to watch. Or at least from 3.00 - 3.40!

http://www.partnering360.com/insight/showroom/id/754